[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fqb1AfhTFfqn6SY4KRuToATur6y2QL8_Oe4qoCkZ8-Ko":8,"$fMQflxRvkpajlvI27AbOIBb4KsYgFUjFkPa28GVTTAvA":57,"$fKAvta3h9rGseQwhrFMvHHthK0yNxOo-FlOiGzfSWY5A":61},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":56},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":28,"isThumbsUp":7,"isCollection":7,"collections":28,"createTime":29,"seoTitle":30,"seoKeywords":31,"seoDescription":32,"shelvesTime":33,"version":28,"menus":34,"menuId":36,"type":44,"quality":55,"commentCount":28,"isComment":44},11208,863041,[],"https://ystcdn.venuertc.com/medical/ystApp/LdA3TTI5CihAACaL8B8KOfe2aOizTBst.png","肖莲春","西昌市人民医院","呼吸内科","主治医师",20,26,"健康了解不容忽视：应对慢性阻塞性肺病和肺源性心脏病的重拳出击！","","https://ystcdn.venuertc.com/venue/AI/efb29753-28a2-4ccd-82b7-28f872db1ba5.jpg","\u003Cp style=\"margin:15px 0\">随着年龄的增长，不少老年人面临着多种健康问题的困扰。今天我们来讨论两种常见的慢性肺部和心脏疾病：慢性阻塞性肺病（COPD）和肺源性心脏病。这些疾病在高龄人士中尤为普遍，了解它们的发病机制、治疗方案和预防措施对促进老年人健康生活非常重要。\u003C/p>\u003Cp style=\"margin:15px 0\">本文旨在通过科学研究和临床经验，为大家提供关于这两种疾病的全面科普，帮助读者更好地理解自身健康状况，并且采取合适的措施保护自己的健康。\u003C/p>\u003Ch3 style=\"margin:20px 0\">慢性阻塞性肺病：不可忽视的老年健康问题\u003C/h3>\u003Cp style=\"margin:15px 0\">慢性阻塞性肺病是一种常见的慢性呼吸道疾病，主要以气流受限为特征。患者常表现为长期咳嗽、咳痰和呼吸困难等症状。COPD的高危因素包括长期吸烟、接触有害气体及职业暴露等。\u003C/p>\u003Cp style=\"margin:15px 0\">慢性阻塞性肺病的严重性不容小觑。研究数据显示，COPD的全球患病率约为14.5%。据《Lancet》期刊报道，COPD已经成为全球第三大死亡原因，造成了巨大的社会和经济负担（来源：Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2017; 390(10100): 1082-1130）。\u003C/p>\u003Ch3 style=\"margin:20px 0\">肺源性心脏病：致命的心肺联动\u003C/h3>\u003Cp style=\"margin:15px 0\">肺源性心脏病，又称“肺心病”，是由于肺部疾病引起的心脏病。慢性阻塞性肺病是肺源性心脏病的常见诱因之一。肺心病的核心机制是由于长期肺部缺氧，导致肺动脉压力增高，进而引发右心室肥大和心力衰竭。\u003C/p>\u003Cp style=\"margin:15px 0\">肺心病的早期症状通常较为隐匿，如轻微的呼吸困难和疲劳感，进展到晚期可出现显著的右心衰竭症状，如下肢水肿、腹水、肝脏肿大等。\u003C/p>\u003Cp style=\"margin:15px 0\">今年《European Heart Journal》上发表一篇综述文章详细揭示了肺源性心脏病的机制和治疗进展。文章指出，肺心病的早期诊断和干预是改善预后、提升生活质量的关键（来源：Hoeper, MM, Pausch, C, Olsson, KM, et al. A comprehensive view on the right ventricle in pulmonary hypertension patients. Eur Heart J. 2020; 41(5): 702-709）\u003C/p>\u003Ch3 style=\"margin:20px 0\">如何应对和治疗这些疾病？\u003C/h3>\u003Cp style=\"margin:15px 0\">针对慢性阻塞性肺病和肺源性心脏病，现代医学提供了多种治疗方法。根据COPD的严重程度，治疗方案通常包括吸入药物、肺康复、氧疗等。吸入药物如长效β2激动剂和抗胆碱药物能有效缓解气道阻塞，提高患者的生活质量。\u003C/p>\u003Cp style=\"margin:15px 0\">对肺源性心脏病，治疗方法主要集中在缓解肺动脉高压和改善右心功能。药物包括磷酸二酯酶-5抑制剂和内皮素受体拮抗剂。此外，还需注意控制原发性肺部疾病。\u003C/p>\u003Cp style=\"margin:15px 0\">梁教授在《Journal of the American College of Cardiology》上的论文中提到，综合治疗方式结合个体化治疗能够显著提升肺心病患者的预后和生活质量（来源：Leung CC, Mahadeva R, Shankar S, et al. Early intervention with combined inhaled corticosteroids/long‐acting beta agonists versus long‐acting beta agonists/inhaled corticosteroids alone in patients with severe COPD: A retrospective cohort analysis. J Am Coll Cardiol. 2018; 73(12): 1509-1519）\u003C/p>\u003Ch3 style=\"margin:20px 0\">预防措施：保护自己，从点滴做起\u003C/h3>\u003Cp style=\"margin:15px 0\">慢性阻塞性肺病和肺源性心脏病的防治关键在于早期的预防和健康管理。老年人是高危人群之一，特别是有长期吸烟史、职业暴露史或家族遗传史的个体，应格外注意自身健康。\u003C/p>\u003Cp style=\"margin:15px 0\">首先，要戒烟。吸烟是COPD最主要的危险因素，戒烟能显著减少发病风险。其次，减少对有害气体和粉尘的暴露，佩戴防护口罩以减少吸入。\u003C/p>\u003Cp style=\"margin:15px 0\">此外，经常进行肺功能检查、保持适度运动、均衡饮食以及定期体检也是非常重要的预防措施。世界卫生组织（WHO）建议，老年人每周至少进行150分钟的中等强度有氧运动，以提高心肺耐力（来源：World Health Organization. Global recommendations on physical activity for health. WHO. 2010）\u003C/p>\u003Ch3 style=\"margin:20px 0\">未来展望：医学技术的新希望\u003C/h3>\u003Cp style=\"margin:15px 0\">随着医学技术的不断发展，针对慢性阻塞性肺病和肺源性心脏病的治疗手段也在不断创新。近年来，基因疗法、干细胞治疗和新型药物研发为患者带来了新的希望。\u003C/p>\u003Cp style=\"margin:15px 0\">例如，基因疗法通过纠正病变基因，已经在动物实验中显示出良好的效果。干细胞治疗则通过再生受损组织，有望成为治疗顽固性肺部和心脏疾病的重要手段。\u003C/p>\u003Cp style=\"margin:15px 0\">面对疾病，心态调整同样重要。患者应保持积极的生活态度，与医生保持良好的沟通与交流。同时，家属也需给予患者充分的支持和理解，共同面对疾病的挑战。\u003C/p>\u003Cp style=\"margin:15px 0\">引用文献\u003C/p>\u003Col style=\"padding: 0 1rem;margin: 1.25rem 1rem 1.25rem 0.4rem\">\u003Cli>\u003Cp style=\"margin:15px 0\">Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2017; 390(10100): 1082-1130.\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">Hoeper, MM, Pausch, C, Olsson, KM, et al. A comprehensive view on the right ventricle in pulmonary hypertension patients. Eur Heart J. 2020; 41(5): 702-709.\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">Leung CC, Mahadeva R, Shankar S, et al. Early intervention with combined inhaled corticosteroids/long‐acting beta agonists versus long‐acting beta agonists/inhaled corticosteroids alone in patients with severe COPD: A retrospective cohort analysis. J Am Coll Cardiol. 2018; 73(12): 1509-1519.\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">World Health Organization. Global recommendations on physical activity for health. WHO. 2010.\u003C/p>\u003C/li>\u003C/ol>","\n\n随着年龄的增长，不少老年人面临着多种健康问题的困扰。今天我们来讨论两种常见的慢性肺部和心脏疾病：慢性阻塞性肺病（COPD）和肺源性心脏病。这些疾病在高龄人士中尤为普遍，了解它们的发病机制、治疗方案和预防措施对促进老年人健康生活非常重要。\n\n本文旨在通过科学研究和临床经验，为大家提供关于这两种疾病的全面科普，帮助读者更好地理解自身健康状况，并且采取合适的措施保护自己的健康。\n\n慢性阻塞性肺病：不可忽视的老年健康问题\n\n慢性阻塞性肺病是一种常见的慢性呼吸道疾病，主要以气流受限为特征。患者常表现为长期咳嗽、咳痰和呼吸困难等症状。COPD的高危因素包括长期吸烟、接触有害气体及职业暴露等。\n\n慢性阻塞性肺病的严重性不容小觑。研究数据显示，COPD的全球患病率约为14.5%。据《Lancet》期刊报道，COPD已经成为全球第三大死亡原因，造成了巨大的社会和经济负担（来源：Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2017; 390(10100): 1082-1130）。\n\n肺源性心脏病：致命的心肺联动\n\n肺源性心脏病，又称“肺心病”，是由于肺部疾病引起的心脏病。慢性阻塞性肺病是肺源性心脏病的常见诱因之一。肺心病的核心机制是由于长期肺部缺氧，导致肺动脉压力增高，进而引发右心室肥大和心力衰竭。\n\n肺心病的早期症状通常较为隐匿，如轻微的呼吸困难和疲劳感，进展到晚期可出现显著的右心衰竭症状，如下肢水肿、腹水、肝脏肿大等。\n\n今年《European Heart Journal》上发表一篇综述文章详细揭示了肺源性心脏病的机制和治疗进展。文章指出，肺心病的早期诊断和干预是改善预后、提升生活质量的关键（来源：Hoeper, MM, Pausch, C, Olsson, KM, et al. A comprehensive view on the right ventricle in pulmonary hypertension patients. Eur Heart J. 2020; 41(5): 702-709）\n\n如何应对和治疗这些疾病？\n\n针对慢性阻塞性肺病和肺源性心脏病，现代医学提供了多种治疗方法。根据COPD的严重程度，治疗方案通常包括吸入药物、肺康复、氧疗等。吸入药物如长效β2激动剂和抗胆碱药物能有效缓解气道阻塞，提高患者的生活质量。\n\n对肺源性心脏病，治疗方法主要集中在缓解肺动脉高压和改善右心功能。药物包括磷酸二酯酶-5抑制剂和内皮素受体拮抗剂。此外，还需注意控制原发性肺部疾病。\n\n梁子铭教授在《Journal of the American College of Cardiology》上的论文中提到，综合治疗方式结合个体化治疗能够显著提升肺心病患者的预后和生活质量（来源：Leung CC, Mahadeva R, Shankar S, et al. Early intervention with combined inhaled corticosteroids/long‐acting beta agonists versus long‐acting beta agonists/inhaled corticosteroids alone in patients with severe COPD: A retrospective cohort analysis. J Am Coll Cardiol. 2018; 73(12): 1509-1519）\n\n预防措施：保护自己，从点滴做起\n\n慢性阻塞性肺病和肺源性心脏病的防治关键在于早期的预防和健康管理。老年人是高危人群之一，特别是有长期吸烟史、职业暴露史或家族遗传史的个体，应格外注意自身健康。\n\n首先，要戒烟。吸烟是COPD最主要的危险因素，戒烟能显著减少发病风险。其次，减少对有害气体和粉尘的暴露，佩戴防护口罩以减少吸入。\n\n此外，经常进行肺功能检查、保持适度运动、均衡饮食以及定期体检也是非常重要的预防措施。世界卫生组织（WHO）建议，老年人每周至少进行150分钟的中等强度有氧运动，以提高心肺耐力（来源：World Health Organization. Global recommendations on physical activity for health. WHO. 2010）\n\n未来展望：医学技术的新希望\n\n随着医学技术的不断发展，针对慢性阻塞性肺病和肺源性心脏病的治疗手段也在不断创新。近年来，基因疗法、干细胞治疗和新型药物研发为患者带来了新的希望。\n\n例如，基因疗法通过纠正病变基因，已经在动物实验中显示出良好的效果。干细胞治疗则通过再生受损组织，有望成为治疗顽固性肺部和心脏疾病的重要手段。\n\n面对疾病，心态调整同样重要。患者应保持积极的生活态度，与医生保持良好的沟通与交流。同时，家属也需给予患者充分的支持和理解，共同面对疾病的挑战。\n\n\n引用文献\nSoriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2017; 390(10100): 1082-1130.\nHoeper, MM, Pausch, C, Olsson, KM, et al. A comprehensive view on the right ventricle in pulmonary hypertension patients. Eur Heart J. 2020; 41(5): 702-709.\nLeung CC, Mahadeva R, Shankar S, et al. Early intervention with combined inhaled corticosteroids/long‐acting beta agonists versus long‐acting beta agonists/inhaled corticosteroids alone in patients with severe COPD: A retrospective cohort analysis. J Am Coll Cardiol. 2018; 73(12): 1509-1519.\nWorld Health Organization. Global recommendations on physical activity for health. WHO. 2010.\n",556,0,"2025-03-14 17:46:01"," 健康了解不容忽视：应对慢性阻塞性肺病和肺源性心脏病的重拳出击！"," 慢性阻塞性肺病, 肺源性心脏病, 健康了解, 疾病预防, 呼吸系统疾病, 心脏健康"," 深入了解慢性阻塞性肺病和肺源性心脏病的危害与预防措施，掌握关键的健康知识，采取积极行动，保护您的呼吸系统和心脏健康。不容忽视的健康了解，重拳出击应对这些严重疾病！","2025-04-04 22:35:00",[35],{"menuId":36,"menuName":37,"parentId":28,"orderNum":38,"path":39,"component":40,"isFrame":41,"isCache":42,"menuType":43,"visible":44,"status":28,"createDept":6,"remark":23,"createTime":45,"children":46,"columnImage":47,"columnLogo":48,"uncheckedLogo":6,"checkedLogo":6,"isHot":44,"isHome":28,"forceLogin":28,"color":49,"seoTitle":50,"seoKeywords":51,"seoDescription":52,"contentNum":6,"promotionalPoster":53,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":54,"routerPath":39,"componentInfo":40},"1986713082609147906","健康科普",2,"article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","慢性病,重大疾病",true,{"code":9,"msg":10,"message":6,"data":58,"success":56},{"pageNo":44,"pageSize":59,"result":60,"totalSize":28},10,[],{"code":9,"msg":10,"message":6,"data":62,"success":56},{"authors":63,"appraiseDimensionScoresVos":64},[],[]]